CeriBell (NASDAQ:CBLL) CEO Sells $41,242.36 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 2,084 shares of CeriBell stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $19.79, for a total transaction of $41,242.36. Following the transaction, the chief executive officer directly owned 725,164 shares in the company, valued at $14,350,995.56. The trade was a 0.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Xingjuan Chao also recently made the following trade(s):

• On Monday, January 5th, Xingjuan Chao sold 79,000 shares of CeriBell stock. The shares were sold at an average price of $21.27, for a total transaction of $1,680,330.00.
• On Thursday, December 4th, Xingjuan Chao sold 25,000 shares of CeriBell stock. The stock was sold at an average price of $18.82, for a total transaction of $470,500.00.
• On Monday, December 1st, Xingjuan Chao sold 25,000 shares of CeriBell stock. The shares were sold at an average price of $16.59, for a total transaction of $414,750.00.

CeriBell Stock Performance

Shares of CeriBell stock opened at $18.67 on Friday. The stock’s fifty day simple moving average is $21.11 and its 200 day simple moving average is $16.26. The company has a current ratio of 9.73, a quick ratio of 12.25 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $702.74 million, a PE ratio of -12.70 and a beta of 1.03. CeriBell, Inc. has a 12 month low of $10.01 and a 12 month high of $24.68.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.07. CeriBell had a negative return on equity of 31.77% and a negative net margin of 59.97%.The company had revenue of $24.78 million during the quarter, compared to the consensus estimate of $23.95 million. On average, research analysts predict that CeriBell, Inc. will post -2.46 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on CBLL shares. Canaccord Genuity Group upped their price target on shares of CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. BTIG Research reaffirmed a “buy” rating and issued a $30.00 price objective on shares of CeriBell in a research report on Wednesday, January 28th. TD Cowen reiterated a “buy” rating on shares of CeriBell in a report on Tuesday, December 9th. Finally, JPMorgan Chase & Co. dropped their price target on CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, CeriBell has an average rating of “Moderate Buy” and a consensus price target of $24.67.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd grew its position in CeriBell by 3,971.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after purchasing an additional 1,231 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of CeriBell in the 3rd quarter valued at about $33,000. CWM LLC raised its holdings in CeriBell by 1,178.5% during the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after acquiring an additional 1,697 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after purchasing an additional 1,801 shares during the last quarter. Finally, Ameritas Investment Partners Inc. grew its stake in CeriBell by 97.5% in the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock valued at $48,000 after purchasing an additional 1,256 shares in the last quarter.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.